Concepedia

Chuen‐Pei Ng

CN

Statistics

Publications

5

Citations

393

H-Index

5

Active since

2001

Affiliations

University of California, Los Angeles(Current)

Chuen‐Pei Ng is an author at University of California, Los Angeles specializing in cell death, apoptosis, and medicine.

Top concepts

Publications per year

2001–2002

5

Publications

5

X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).

Chuen‐Pei Ng, Benjamin Bonavida · PubMed · 2002 · 99 citations

, , +18

Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL‐mediated apoptosis of prostate cancer cells: Role of XIAP in resistance

Chuen‐Pei Ng, Amnon Zisman, Benjamin Bonavida · The Prostate · 2002 · 93 citations

Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.

Steve Alas, Chuen‐Pei Ng, Benjamin Bonavida · PubMed · 2002 · 89 citations

Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.

Ali R. Jazirehi, Chuen‐Pei Ng, Xiao-Hu Gan et al. · PubMed · 2001 · 57 citations

, , +15

Actinomycin D and Gemcitabine Synergistically Sensitize Androgen-Independent Prostate Cancer Cells to Apo2L/TRAIL-Mediated Apoptosis

Amnon Zisman, Chuen‐Pei Ng, Allan J. Pantuck et al. · Journal of Immunotherapy · 2001 · 55 citations

, , +12

1–5 of 5